How Oncotarget is Benefiting Cancer Researchers

Cancer is one of the most researched illnesses. Just like it is the case with other medical studies, researchers often find it hard to publish their findings. This is partly caused by difficulties in finding notable journals to publish these findings in them. Thanks to Oncotarget, cancer researchers have a platform for disseminating information pertaining to oncological research.

Since its establishment in 2010, Oncotarget has established itself as a prominent journal, which mainly focuses on cancer research and oncology. This weekly publication is meant for articles focusing on ongoing oncological research. All articles that are published in the journal are peer reviewed to ensure that they meet academic and scientific standards. The articles are exclusively published in English. Nonetheless, Oncotarget is available globally since it accepts articles and papers from researchers from across the globe.

How the Journal Operates

Oncotarget is the brainchild of renowned researchers, Mikhail Blagosklonny and Andrei V. Gudkov. Both are experienced oncologists and serve as the journal’s co-editors-in-chief besides undertaking their own research. Oncotarget is popular with scientists due to its prominence and meticulous peer review process, which is spearheaded by a competent editorial board comprising of healthcare professionals who are associated with notable institutions.

Oncotarget’s reputation is attested to by the fact that is indexed via Index Medicus/MEDLINE/PubMed, the Science Citation Index Expanded, Scopus, and BIOSIS Previews. In as much as it mainly targets cancer and oncology research, articles that are associated with other related areas are also accepted by the editorial board. Researchers who want their articles published on the journal can easily find information about the submission and peer review process on the publication’s website.

Learn more: http://endnote.com/downloads/style/oncotarget

Oncotarget is itself published by Impact Journals. By virtue of being an open source journal, its articles are available at no fee. This is due to the journal’s dedication towards disseminating free information about cancer research to the medical community. This goes a long way in enhancing ongoing research besides beefing up the existing body of knowledge. Oncotarget also partners with prestigious institutions such as Jon Hopkins, Columbia, and Harvard universities. Its founders work at the Roswell Cancer Institute. This explains why the journal has gained prominence within a relatively short time. Follow Oncotarget journal on Twitter.